President Donald Trump's executive order on Monday directing U.S. health regulators to accelerate the review of psychedelic treatments drove AtaiBeckley (ATAI) shares up more than 21% by the close. The White House's action focuses on expediting regulatory evaluation timelines for drugs with breakthrough-therapy designations from the FDA, allowing reviews to be completed in as little as one to two months, according to industry commentary.
Stocks365 Take: Analyst Ratings Underpin Small HubSpot Bounce, but 2026 Losses Remain Steep
While the policy shift was the day's clear catalyst for AtaiBeckley, HubSpot (HUBS) rose modestly after Macquarie reiterated its "Outperform" rating and $350 price target, supported by Cantor Fitzgerald's $325 and Truist's $300 target. After an early jump to 2.5%, shares closed at $227.10, up 2.1% from the previous session. Despite the uptick, HubSpot remains down 40.6% year-to-date and sits 66.2% below its 52-week high of $672.24 reached in May 2025, reflecting a volatile and challenging period for growth software multiples.
AtaiBeckley Positioned for Fast-Tracked Review if FDA Implements Trump's Order
AtaiBeckley holds a market cap of about $1.8 billion and is developing BPL-003, a nasal spray for treatment-resistant depression. BPL-003 has already received breakthrough therapy designation and showed positive results in Phase 2, with Phase 3 trials expected to begin later this year. If FDA agencies adjust faster timelines per the executive order, AtaiBeckley could see regulatory decisions sooner than previously expected, although implementation details depend on FDA action.
What to Watch: FDA Clarity, HubSpot's Next Earnings, and Analyst-Market Disconnect
Investors should watch for: (1) potential FDA communications clarifying how and when the expedited review timelines may apply to psychedelic compounds; (2) whether HubSpot can demonstrate results with its AI product push ahead of its next earnings, as analyst targets remain well above current pricing; and (3) ongoing volatility in key sector names as the market adjusts to both new regulatory signals and shifting risk preferences for high-growth stocks.